Plain-English translation of NCT03792919 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people with chronic hepatitis B can safely stop taking nucleos(t)ide analogues—medications like entecavir or tenofovir that stop the virus from multiplying—after their virus has been controlled for a long time. Researchers want to know whether stopping the medication might help more patients' bodies clear the virus completely, or whether it's safer to keep taking the medication indefinitely.
Current antiviral medications work very well at controlling hepatitis B, but they rarely lead to complete viral clearance. Recent studies suggest that stopping the medication might actually trigger the body's immune system to clear the virus more effectively, so doctors want to study this carefully to see which patients can safely stop treatment and which should continue.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be assigned to either stop taking your current medication or continue taking it. The study will then follow you over time with regular blood tests to check your viral levels and see how your liver is doing. You'll be monitored to make sure your health remains stable whether you stopped the medication or kept taking it.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
Hong Kong
Phase
Post-approval monitoring
Sponsor
Humanity & Health Medical Group Limited
Enrollment target
~2,000 participants
Started
December 2018
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
George Lau, MD
Humanity & Health Medical Group Limited
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.